Weekly low-dose pulsed methotrexate in ocular Behcet (analysis of 41 cases).


Abstract: Cytotoxic drugs as the only remittent agents in posterior uveitis (PU) and/or retinal vasculitis (RV) of Aehcet's disease(BD) is generally accepted today. However which cytotoxic is the least harmful and yet efficient is questionable. The safety of long term use of MTX in rheumatoid arthritis made us to use this drug in ocular Behcet. Our prelimi-nary report to the first APLAR Symposium for Treatment of Rheumatic Diseases in Korea, stowed the ef-ficiency of this method. Now we present here our latest results in 41 patients. MTX was administered 7.5 my weekly , in 3 divided doses every 12 hours, plus prc:dnisolone 0.5 mg/kg/day. A Disease Activity Index (DAI) based upon the inflammatory state of each section of each eye was calculated at each clinical control. The first and the last one were compared by the Student paired t test. ,After a mean follow up time of 7:4 months, PU was improved in 70% of patients. The mean DAI improved from 2.1 to 1.1 (t=5.4N5, •p<0.00(l0(1?). RV,wns improved in 62% of the eyes. The mean UAT was reduced from 1.5 to 0.9 (t.=?..44fl, p=U.017(1). The mean vir.ual acuity im-proved from 4.1 to 5.9 r;a 10 by the Suellon chart (t=6.62f, p